1. Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications
- Author
-
Roberta Bottino, Dario Galante, Nadia Della Cioppa, Anna Rago, Ernesto Ammendola, Vincenzo Russo, Gerardo Nigro, Paolo Golino, Andreina Carbone, Russo, Vincenzo, Rago, Anna, Carbone, Andreina, Bottino, Roberta, Ammendola, Ernesto, Della Cioppa, Nadia, Galante, Dario, Golino, Paolo, and Nigro, Gerardo more...
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Pneumonia, Viral ,030204 cardiovascular system & hematology ,Antiviral Agents ,03 medical and health sciences ,Betacoronavirus ,0302 clinical medicine ,Risk Factors ,Epidemiology ,Pandemic ,Atrial Fibrillation ,medicine ,Humans ,Drug Interactions ,Intensive care medicine ,Pandemics ,Pharmacology ,business.industry ,Viral Epidemiology ,SARS-CoV-2 ,Public health ,Outbreak ,virus diseases ,Anticoagulants ,COVID-19 ,Atrial fibrillation ,medicine.disease ,COVID-19 Drug Treatment ,Pneumonia ,030104 developmental biology ,Treatment Outcome ,Host-Pathogen Interactions ,business ,Cardiology and Cardiovascular Medicine ,Coronavirus Infections ,Anti-Arrhythmia Agents - Abstract
Coronavirus disease 2019 (COVID-19) outbreak is a public health emergency of international concern due to a highly pathogenic human coronavirus (HCoV), actually named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite much emerging data about the epidemiological association between cardiovascular diseases and COVID-19, little is still known atrial fibrillation (AF) and its optimal management in this clinical contest. The aim of our review is to describe the pharmacological interactions between cardiovascular drugs more commonly used in AF management and experimental COVID-19 therapies, based on European (EU) and Unites States (US) summaries of product characteristics. more...
- Published
- 2020